G
Genprex, Inc.
GNPXCIK 0001595248NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsTexasFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-16.20M
Total Assets
$10.16M
Equity
$7.96M
Shares Out
9.04M
Op. Cash Flow
$-15.31M
Business
Genprex, Inc. is a clinical-stage gene therapy company developing systemic and local gene-based therapies for cancer and diabetes. Its main products and technologies include REQORSA, a TUSC2-expressing plasmid encapsulated in the ONCOPREX® non-viral lipid nanoparticle delivery system, and GPX-002, an AAV-based construct delivering Pdx1 and MafA for pancreatic cell reprogramming. The company operates distinct oncology and diabetes programs, with a retained oncology portfolio and a newly formed subsidiary, Convergen Biotech, to focus on diabetes. Its development and distribution activities are conducted through U.S. clinical trials, academic collaborations, and third-party CDMOs for manufacturing.
Summary from filing dated 2025-04-01
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 0 | 6,693 | 15,004 | 25,575 | 22,534 | |
| Research and development | 9 | 11 | 18 | 12 | 9 | |
| General and administrative | 6 | 11 | 13 | 12 | 12 | |
| Total operating expenses | 16 | 21 | 31 | 24 | 21 | |
| Operating loss | −16 | −21 | −31 | −24 | −21 | |
| Other income | 26,900 | 63,574 | — | — | — | |
| Other financing costs | −739,935 | 0 | — | — | — | |
| Realized and unrealized loss | −299 | −570 | −18,676 | — | — | |
| Net loss | −16 | −21 | −31 | −24 | −21 | |
| Deemed dividend related to warrant modification | 0 | −277,119 | 0 | — | — | |
| Net loss attributable to common stockholders | −16 | −21 | −31 | — | — | |
| Net loss per share applicable to common stockholders basic and diluted (in dollars per share) | −17.4 | −266.89 | −22.56 | −19.8 | −0.44 | |
| Weighted average number of common shares basic and diluted (in shares) | 932,730 | 80,139 | 1 | 1 | 47 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 8 | 2 | 7 | 21 | — | |
| Prepaid expenses and other | 525,928 | 475,807 | 794,138 | 484,224 | — | |
| Total current assets | 8 | 2 | 8 | 21 | — | |
| Property and equipment, net | 0 | 0 | 7,859 | 23,032 | — | |
| Research and development supplies | 2 | 2 | 2 | 3 | — | |
| Total non-current assets | 2 | 2 | 3 | 4 | — | |
| Total assets | 10 | 4 | 11 | 25 | 30 | |
| Accounts payables | 743,070 | 1 | 1 | 442,925 | — | |
| Other current liabilities | 1 | 1 | 2 | 2 | — | |
| Total current liabilities | 2 | 3 | 3 | 3 | — | |
| Derivative liabilities | 22,500 | 0 | — | — | — | |
| Total liabilities | 2 | 3 | — | — | — | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 0 | 0 | 0 | — | — | |
| Common stock $0.001 par value: 200,000,000 shares authorized; 3,291,488 and 217,234 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 3,291 | 217 | 1,486 | 1,203 | 48,020 | |
| Additional paid-in capital | 179 | 156 | 141 | 125 | 124 | |
| Accumulated deficit | −171 | −155 | −134 | −103 | −96 | |
| Total stockholders' equity | 8 | 2 | 7 | 22 | 27 | |
| Total liabilities and stockholders' equity | 10 | 4 | 11 | 25 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Prepaid expenses and other | −50,120 | 328,330 | −298,096 | 27,125 | −126,795 | |
| Research and development supplies | 244,630 | 300,630 | 517,449 | 157,465 | — | |
| Accounts payable | −331,226 | −323,315 | 954,686 | −530,269 | 780,226 | |
| Other current liabilities | 1,690 | −426,723 | −510,765 | 2 | 354,344 | |
| Net cash used in operating activities | −15 | −18 | −25 | −18 | −14 | |
| Disposals of property and equipment | 0 | 1,166 | 169 | 0 | — | |
| Reductions to intellectual property | 0 | 773,478 | — | — | — | |
| Net cash provided by investing activities | 0 | 774,644 | −71,214 | −59,735 | −83,796 | |
| Net proceeds from issuances of common stock | 22 | 12 | 11 | 6,426 | 26 | |
| Net cash provided by financing activities | 22 | 12 | 11 | 6,426 | 26 | |
| Net increase (decrease) in cash and cash equivalents | 6 | −5 | −14 | −18 | 11 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro